JAK2 and essential thrombocythemia: In another study conducted in the 108 cases with CMDs cases in Taiwan by Liu et al, JAK2 mutation was found to be positive in 85% (28.33) PV cases, 59% of patients (29.49) in ET patients, 33% (2.6) in PMF cases, (0.11) in MDS patients, and (0.10) in the other cases with 10 different hematological diseases (13).